Platform enhances perfusion bioprocessing efficiency and scalability

Celonic Group, a leading Swiss-based contract development and manufacturing organisation (CDMO), has integrated Merck’s Breez™ micro-bioreactor platform into its process development workflow. This strategic integration enhances Celonic’s expertise in monoclonal antibody (mAb) development and manufacturing, enabling highly efficient, scalable perfusion-based bioprocessing from early-stage development to commercial-scale production.

The Breez™ 2 mL micro-bioreactor platform is an automated, functionally closed, continuous perfusion cell culture system. By leveraging this advanced technology, Celonic is optimising upstream processes to accelerate product development, reduce the cost of goods per gram, and significantly improve operational efficiency in biologics production.

“This collaboration marks a pivotal moment in our commitment to advancing bioprocessing solutions,” said Samanta Cimitan, PhD, CEO of Celonic Group. “The Breez™ platform enables us to scale our production capabilities, enhance productivity, and reduce costs, benefiting both our clients and the patients who rely on these biologics.”

More information online